Prolexys Pharmaceuticals and Columbia U, BD Biosciences, StemCell Technologies and WARF, and Molecular Devices | GenomeWeb
Prolexys and Columbia Publish Study On Erastin Mechanism of Action
 
Prolexys Pharmaceuticals and Columbia University this week announced a publication describing the properties of erastin, a selective small-molecule anti-tumor agent.
 
Prolexys and Columbia applied Prolexys’ chemi-proteomics technology to understand erastin’s mechanism of action. They found that erastin binds to mitochondrial voltage-dependent anion channels — a novel target for anti-cancer drugs.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.